European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
1640
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’260
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices146
Striving for the ‘perfect’ definition of iron deficiency in heart failure145
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up135
Letter regarding the article ‘Employment of artificial intelligence for an unbiased evaluation regarding the recovery of right ventricular function after mitral valve transcatheter edge‐to‐edge repair127
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h123
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’115
Heart failure: age is no excuse for complacency108
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail103
Expanding the horizon of medication adherence strategies in acutely decompensated heart failure. Letter regarding the article ‘Medication adherence in patients with acutely decompensated heart failure102
Abstract100
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters99
Issue Information89
Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction89
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial80
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure 76
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians71
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management71
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices69
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock67
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE66
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato65
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?64
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials64
Determinants of submaximal exercise intolerance in patients with heart failure and preserved ejection fraction: Insights from the lactate threshold63
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases63
Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology63
Issue Information63
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial62
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival61
Abstract61
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF60
Risk factors for the development of heart failure in patients with or without prior myocardial infarction60
Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC59
Issue Information59
Dissecting the heart failure phenotype through phenomics59
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery58
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial58
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial57
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology57
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial57
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials56
Issue Information56
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction55
Correction to “Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence a55
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities55
Issue Information55
Normal and excessive muscle sympathetic nerve activity in heart failure: implications for future trials of therapeutic autonomic modulation54
Reply to the letter regarding the article ‘Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care’54
Cardiopulmonary functional capacity: another piece of the puzzle of sodium–glucose cotransporter 2 inhibition in heart failure?54
Predicting survival in patients with severe heart failure: Risk score validation in the HELP‐HF cohort53
Finerenone according to insulin resistance in heart failure: Insights from the FINEARTS‐HF trial53
Letter regarding the article ‘Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction’53
0.51202178001404